Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:TKMR) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.


In addition to our HBV Assets, we are developing a pipeline of Oncology, Anti-viral and Metabolic Programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.

View all »   RSSRecent Releases

Aug 25, 2015
Arbutus Announces Initiation of Patient Dosing in the TKM-PLK1 HCC Expansion Cohort

Aug 7, 2015
Arbutus to Present at 2015 Wedbush PacGrow Healthcare Conference

View all »Events & Presentations

Aug 11, 2015 at 11:30 AM PT
2015 Wedbush PacGrow Healthcare Conference

Aug 6, 2015 at 10:45 AM ET
Jefferies Hepatitis B Summit